Human Immunology Biosciences
Human Immunology Biosciences, based in South San Francisco, focuses on developing targeted therapies for severe immune-mediated diseases, leveraging genetic and immunological insights.
Company Overview
Human Immunology Biosciences leverages human genetic and immunological insights to deliver targeted therapies for severe immune-mediated diseases. Located at 6000 Shoreline Court, Suite 304, South San Francisco, CA 94080, the company focuses on clinical-stage programs and maintains a robust pipeline addressing various diseases across the immune landscape.
Targeted Therapies
Human Immunology Biosciences is dedicated to developing targeted therapies for severe immune-mediated diseases. Its clinical-stage programs are informed by human genetic and immunological research, aiming to provide effective treatments for complex immune disorders. The company's pipeline encompasses therapies for a range of immune-mediated conditions.
Key Products
Human Immunology Biosciences is known for its development of Felzartamab and Izastobart/HIB210. Felzartamab has received the FDA's Orphan Drug Designation for the treatment of Antibody-Mediated Rejection in kidney transplant recipients and Breakthrough Therapy Designation for Primary Membranous Nephropathy. Izastobart/HIB210 is an anti-C5aR1 antibody with potential for treating complement-mediated diseases. The company holds exclusive worldwide rights for both therapies, with the exception of Greater China and, for Izastobart/HIB210, South Korea.
FDA Designations
Human Immunology Biosciences has achieved significant milestones with FDA designations for its products. Felzartamab received the Orphan Drug Designation for treating Antibody-Mediated Rejection in kidney transplant recipients and the Breakthrough Therapy Designation for Primary Membranous Nephropathy. These designations underscore the company's commitment to advancing therapies for critical immune-mediated diseases.
Recent Financing
In its latest funding round, Human Immunology Biosciences announced a $95 million Series B financing. This substantial investment is aimed at advancing the development of targeted therapies for immune-mediated diseases, supporting the company's mission to innovate in the field of immunology.